AIM ImmunoTech Inc. (AIM) vs Soligenix Inc. (SNGX)

AIM ImmunoTech Inc. and Soligenix Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Soligenix Inc. are of similar size ($8.4M and $8.0M). AIM ImmunoTech Inc. grew revenue faster over the last twelve months: −21.5% against −50.4%. Soligenix Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Soligenix Inc. leads on 11 and AIM ImmunoTech Inc. on 6.

Valuation

Metric AIM SNGX Biotechnology median
P/E n/m n/m 7.88
P/S 34.24 12.26 11.47
P/B 0.42 0.91 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.65 0.12 0.74
EV/Sales (66.26) (2.76) 10.73
Earnings yield (1,537.53%) (194.53%) (28.84%)
Free cash flow yield (449.55%) (160.81%) (23.03%)

Profitability

Metric AIM SNGX Biotechnology median
Gross margin (23.16%) 0.00% 65.16%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (241.65%) (57.72%)
Return on assets (169.28%) (125.95%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM SNGX Biotechnology median
Revenue growth (TTM) (21.49%) (50.37%) 5.64%
EPS growth (last fiscal year) 72.19% 57.03% —
Revenue growth, 5-year CAGR (11.60%) (51.88%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM SNGX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 2.77 4.73
Net debt to EBITDA 0.22 0.67 0.96

Dividend

Metric AIM SNGX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AIM SNGX Biotechnology median
Market cap 7.97m 8.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack